Immuno-Biological Laboratories Co., Ltd. (TYO:4570)
896.00
-1.00 (-0.11%)
Nov 18, 2026, 10:15 AM JST
TYO:4570 Revenue
Immuno-Biological Laboratories had revenue of 277.00M JPY in the quarter ending September 30, 2026, with 1.09% growth. This brings the company's total for the last twelve months to 1.08B, up 7.13% year-over-year. In the fiscal year ending March 31, 2026, Immuno-Biological Laboratories had annual revenue of 1.00B with 3.61% growth. That makes Immuno-Biological Laboratories the 38,955th largest company in the world by revenue and 3,780th in Japan.
Revenue (ttm)
1.08B
Revenue Growth
+7.13%
P/S Ratio
7.72
Revenue / Employee
20.04M
Employees
54
Market Cap
8.34B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full TYO:4570 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.00B | 35.00M | 3.61% |
| Mar 31, 2025 | 969.00M | 153.00M | 18.75% |
| Mar 31, 2024 | 816.00M | 22.00M | 2.77% |
| Mar 31, 2023 | 794.00M | 147.00M | 22.72% |
| Mar 31, 2022 | 647.00M | 45.00M | 7.48% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 5.79B |
| StemCell Institute | 2.81B |
| ReproCELL | 2.42B |
| AnGes | 962.00M |
| Carna Biosciences | 756.57M |
| CellSeed | 161.00M |
| ADR Biomedical Holdings | 101.00M |
| Kubota Pharmaceutical Holdings | 16.00M |